国产瑞舒伐他汀与阿托伐他汀对行择期经皮冠状动脉介入术的急性冠脉综合征患者近期疗效比较

Short-term Efficacy of Domestic PCI and Atorvastatin in the Treatment of ACS

目的：探讨行择期经皮冠状动脉介入术（PCI）的急性冠脉综合征（ACS）患者,比较国产瑞舒伐他汀与阿托伐他汀,常规剂量的近期疗效情况.方法：获得医院伦理委员会和患者及家属的知情同意,收集2012年1月～2014年12月,来我院求诊的ACS患者需行择期PCI的共80例,随机分为瑞舒伐他汀组（国产瑞舒伐他汀组,口服,每日1次,1次10 mg）40例和阿托伐他汀组（阿托伐他汀,口服,每日1次,1次20mg） 40例.比较两组患者PCI手术前后低密度脂蛋白和高密度脂蛋白、超敏C反应蛋白（hsCRP）、观察术后1个月的心血管不良事件（MACE）和chemerin值情况.结果：PCI择期术后,瑞舒伐他汀组的高密度脂蛋白升高和低密度脂蛋白降低、chemerin值的降低、hsCRP值降低情况,明显优于阿托伐他汀组,差异均有统计学意义（P均＜ 0.05）.瑞舒伐他汀组和阿托伐他汀组MACE发生率,不具有显著差异（P＞0.05）.结论：ACS患者行择期PCI术采用瑞舒伐他汀组和阿托伐他汀组治疗,均较安全,瑞舒伐他汀组在显著降低血脂情况,降低chemerin值和hsCRP值方面优于阿托伐他汀组,考虑临床推广.

OBJECTIVE ： To investigate the clinical efficacy of PCI in the patients undergoing elective percutaneous coronary in- tervention （ACS）. METHODS： From January 2012 to December 2014, 80 patients with ACS undergoing PCI in our hospital were di- vided into rosuvastatin group （oral, once a day, 10 mg daily） （n =40） and atorvastatin group （oral, once a day, 20 mg daily） （n =40）. In two groups after operation low density lipoprotein, high density lipoprotein and hsCRP （Chao Min C reaction protein） were compared one month after the observation. Cardiovascular events （MACE） and Chemerin value were observed. RESULTS： The high density lipoprotein, low density lipoprotein and hsCRP were significantly higher than those in atorvastatin group. There were sta- tistically significant difference （PCI 〈 0. 05）. There was no significant difference in the incidence of MACE between the two groups （ P 〉 0. 05 ）. CONCLUSION ： The patients with ACS are treated by PCI, which is safe.